BioCentury
ARTICLE | Clinical News

Immuron reports Phase II data for NASH candidate

March 23, 2018 6:51 PM UTC

Immuron Ltd. (ASX:IMC; NASDAQ:IMRN) reported top-line data from a Phase II trial in 133 patients with non-alcoholic steatohepatitis (NASH) showing that a significantly greater proportion of patients who received oral IMM-124E achieved a ≥15% reduction in serum lipopolysaccharide (LPS) levels vs. placebo (64% vs. 34%, p=0.01843). There was no significant difference between treatment arms in the proportion of patients who achieved a ≥30% reduction in mean serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels (p=0.107 for both). IMM-124E also had no significant effect on hepatic steatosis.

IMM-124E was well tolerated with no serious adverse events reported. Patients in the double-blind, international trial received placebo or thrice-daily 600 or 1,200 mg IMM-124E for 24 weeks. A significantly greater proportion of patients who received high-dose IMM-124E achieved a ≥15% reduction in serum cytokeratin 18 (CK18; KRT18) levels vs. placebo (39% vs. 18%, p=0.0494)...

BCIQ Company Profiles

Immuron Ltd.

BCIQ Target Profiles

Lipopolysaccharide (LPS)